delpacibart etedesiran (AOC 1001) / Avidity Biosci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
delpacibart etedesiran (AOC 1001) / Avidity Biosci
HARBOR, NCT06411288: Global Study of Del-desiran for the Treatment of DM1

Recruiting
3
150
Europe, Canada, Japan, US
AOC 1001 (del-desiran), Placebo
Avidity Biosciences, Inc.
DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
10/26
04/27
MARINA-OLE, NCT05479981: Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Active, not recruiting
2
37
US
Placebo, Saline, AOC 1001
Avidity Biosciences, Inc.
DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
06/27
06/27
MARINA, NCT05027269: Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Completed
1/2
38
US
AOC 1001, Placebo
Avidity Biosciences, Inc.
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
02/23
02/23

Download Options